FDA expands scope of Novartis’ Promacta

19th November 2018 Uncategorised 0

US regulators have expanded the scope of Novartis’ Promacta to include earlier use of the drug to treat adults and paediatric patients with severe aplastic anaemia (SAA) in combination with standard immunosuppressive therapy (IST).

More: FDA expands scope of Novartis’ Promacta
Source: News